|
1
|
Sung H, Filho AM, Laversanne M, Ferlay J,
Siegel RL, Soerjomataram I, Jemal A and Bray F: Global cancer
statistics 2024: GLOBOCAN estimates of incidence and mortality
worldwide for 34 cancers in 186 countries. CA cancer J Clin.
76:e700902026.PubMed/NCBI
|
|
2
|
Wang Z, Shen N, Wang Z, Yu L, Yang S, Wang
Y, Liu Y, Han G and Zhang Q: TRIM3 facilitates ferroptosis in
non-small cell lung cancer through promoting SLC7A11/xCT K11-linked
ubiquitination and degradation. Cell Death Differ. 31:53–64. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang L, Wang D, Zeng L, Chen S, Li K,
Yuan T, Wang J, Ma X, Zhu S and Wu Y: FHL2 facilitates LUSC growth
and therapy resistance through PI3K/AKT/mTOR activation. J Biol
Chem. 301:1103322025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yi C, Zang N, Gao L and Ren F: THY1 is a
prognostic-related biomarker via mediating immune infiltration in
lung squamous cell carcinoma (LUSC). Aging (Albany NY).
16:9498–9517. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu X, Liu J, Xie R, Chang M, Xu B, Zhu Y,
Xie Y and Yang S: Construction of a prognostic model for lung
squamous cell carcinoma based on seven N6-methylandenosine-related
autophagy genes. Math Biosci Eng. 18:6709–6723. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo L, Deng J and Tang Q: A four-gene
autophagy-related prognostic model signature and its association
with immune phenotype in lung squamous cell carcinoma. Cancer Rep
(Hoboken). 7:e700002024.PubMed/NCBI
|
|
7
|
Liu BH, Xu CZ, Liu Y, Lu ZL, Fu TL, Li GR,
Deng Y, Luo GQ, Ding S, Li N and Geng Q: Mitochondrial quality
control in human health and disease. Mil Med Res.
11:322024.PubMed/NCBI
|
|
8
|
Roca-Portoles A and Tait SWG:
Mitochondrial quality control: From molecule to organelle. Cell Mol
Life Sci. 78:3853–3866. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang C, Cai J, Yin XM, Weinberg JM,
Venkatachalam MA and Dong Z: Mitochondrial quality control in
kidney injury and repair. Nat Rev Nephrol. 17:299–318. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Youle RJ and van der Bliek AM:
Mitochondrial fission, fusion, and stress. Science. 337:1062–1065.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Broda M, Millar AH and Van Aken O:
Mitophagy: A mechanism for plant growth and survival. Trends Plant
Sci. 23:434–450. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hernando-Rodríguez B and Artal-Sanz M:
Mitochondrial quality control mechanisms and the PHB (Prohibitin)
complex. Cells. 7:2382018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tran HC and Van Aken O: Mitochondrial
unfolded protein-related responses across kingdoms: Similar
problems, different regulators. Mitochondrion. 53:166–177. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng X, Xu H, Gong L, Cao D, Jin T, Wang
Y, Pi J, Yang Y, Yi X, Liao D, et al: Vinculin orchestrates
prostate cancer progression by regulating tumor cell invasion,
migration, and proliferation. Prostate. 81:347–356. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roth KG, Mambetsariev I, Kulkarni P and
Salgia R: The mitochondrion as an emerging therapeutic target in
cancer. Trends Mol Med. 26:119–134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu L, Wu W, Jiang S, Yu S, Yan Y, Wang K,
He J, Ren Y and Wang B: Pan-cancer analysis of the
mitophagy-related protein PINK1 as a biomarker for the
immunological and prognostic role. Front Oncol. 10:5698872020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bueno M and Rojas M: Lost in translation:
endoplasmic reticulum-mitochondria crosstalk in idiopathic
pulmonary fibrosis. Am J Respir Cell Mol Biol. 63:408–409. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang D, Cui H, Xie N, Banerjee S, Liu RM,
Dai H, Thannickal VJ and Liu G: ATF4 mediates mitochondrial
unfolded protein response in alveolar epithelial cells. Am J Respir
Cell Mol Biol. 63:478–489. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS one.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bueno R, Richards WG, Harpole DH, Ballman
KV, Tsao MS, Chen Z, Wang X, Chen G, Chirieac LR, Chui MH, et al:
Multi-institutional prospective validation of prognostic mRNA
signatures in early stage squamous lung cancer (Alliance). J Thorac
Oncol. 15:1748–1757. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Der SD, Sykes J, Pintilie M, Zhu CQ,
Strumpf D, Liu N, Jurisica I, Shepherd FA and Tsao MS: Validation
of a histology-independent prognostic gene signature for
early-stage, non-small-cell lung cancer including stage IA
patients. J Thorac Oncol. 9:59–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie Y, Xiao G, Coombes KR, Behrens C,
Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, et al:
Robust gene expression signature from formalin-fixed
paraffin-embedded samples predicts prognosis of non-small-cell lung
cancer patients. Clin Cancer Res. 17:5705–5714. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang S, Guo H, Wang H, Liu X, Wang M, Liu
X, Fan Y and Tan K: A novel mitochondrial unfolded protein
response-related risk signature to predict prognosis, immunotherapy
and sorafenib sensitivity in hepatocellular carcinoma. Apoptosis.
29:768–784. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao T, Li Q, Huang Y and Li A:
plotnineSeqSuite: A python package for visualizing sequence data
using ggplot2 style. BMC Genomics. 24:5852023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leek JT, Johnson WE, Parker HS, Jaffe AE
and Storey JD: The sva package for removing batch effects and other
unwanted variation in high-throughput experiments. Bioinformatics.
28:882–883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi S, Qi X, Luo F, Wang D, Feng Z, Ma L,
Yu W, Wang C, Tian H and Lu M: TFIIB-related factor 2 inhibits lung
squamous carcinoma cell apoptosis through SLC8A3-mediated
mitochondrial homeostasis. Cell Death Dis. 16:4912025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z,
Feng T, Zhou L, Tang W, Zhan L, et al: clusterProfiler 4.0: A
universal enrichment tool for interpreting omics data. Innovation
(Camb). 2:1001412021.PubMed/NCBI
|
|
30
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li H, Luo B, Tulufu Y, Wang X and Yue D: A
super-enhancer-related gene signature predicts prognosis and immune
microenvironment features in glioma. Cell Mol Biol
(Noisy-le-Grand). 71:102–109. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maeser D, Gruener RF and Huang RS:
oncoPredict: An R package for predicting in vivo or cancer patient
drug response and biomarkers from cell line screening data. Brief
Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang L, Wang X, Sun B, Sun Y, Chen J,
Jiang J, Meng L, He S, Li R and Wang F: Almonertinib inhibits liver
cancer progression by triggering autophagy-dependent ferroptosis
through inhibition of the PI3K/Akt1/mTOR pathway. Biochem
Pharmacol. 245:1176282026. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gu MM, Gao D, Yao PA, Yu L, Yang XD, Xing
CG, Zhou J, Shang ZF and Li M: p53-inducible gene 3 promotes cell
migration and invasion by activating the FAK/Src pathway in lung
adenocarcinoma. Cancer Sci. 109:3783–3793. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang DG, Wang J, Gao J, Ao YQ, Long X, Zhu
SQ, Zeng ZH, Zhang LX, Chen SW, Pei X and Wu YB: Circ_0002638
drives squamous cell lung cancer (LUSC) progression and
chemotherapy resistance by inhibiting ferroptosis via
SENP1-mediated deSUMOylation of ACSL4. Life Sci. 376:1237282025.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng P and Haynes CM: Mitochondrial
dysfunction in cancer: Potential roles of ATF5 and the
mitochondrial UPR. Semin Cancer Biol. 47:43–49. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lai C, Zhang J, Tan Z, Shen LF, Zhou RR
and Zhang YY: Maf1 suppression of ATF5-dependent mitochondrial
unfolded protein response contributes to rapamycin-induced
radio-sensitivity in lung cancer cell line A549. Aging (Albany NY).
13:7300–7313. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Anderson NS and Haynes CM: Folding the
mitochondrial UPR into the integrated stress response. Trends Cell
Biol. 30:428–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen H, Zhang DM, Zhang ZP, Li MZ and Wu
HF: SIRT3-mediated mitochondrial unfolded protein response weakens
breast cancer sensitivity to cisplatin. Genes Genomics.
43:1433–1444. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kumar R, Chaudhary AK, Woytash J, Inigo
JR, Gokhale AA, Bshara W, Attwood K, Wang J, Spernyak JA, Rath E,
et al: A mitochondrial unfolded protein response inhibitor
suppresses prostate cancer growth in mice via HSP60. J Clin Invest.
132:e1499062022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zeng C, Zhong L, Liu W, Zhang Y, Yu X,
Wang X, Zhang R, Kang T and Liao D: Targeting the lysosomal
degradation of Rab22a-NeoF1 fusion protein for osteosarcoma lung
metastasis. Adv Sci (Weinh). 10:e22054832023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Agnihotri S, Golbourn B, Huang X, Remke M,
Younger S, Cairns RA, Chalil A, Smith CA, Krumholtz SL, Mackenzie
D, et al: PINK1 is a negative regulator of growth and the warburg
effect in glioblastoma. Cancer Res. 76:4708–4719. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu L, Zuo Z, Lu S, Wang L, Liu A and Liu
X: Silencing of PINK1 represses cell growth, migration and induces
apoptosis of lung cancer cells. Biomed Pharmacother. 106:333–341.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rose K, Herrmann E, Kakudji E, Lizarrondo
J, Celebi AY, Wilfling F, Lewis SC and Hurley JH: In situ cryo-ET
visualization of mitochondrial depolarization and mitophagic
engulfment. Proc Natl Acad Sci USA. 122:e25118901222025. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li Y, Qiu L, Liu X, Hou Z and Yu B: PINK1
alleviates myocardial hypoxia-reoxygenation injury by ameliorating
mitochondrial dysfunction. Biochem Biophys Res Commun. 484:118–124.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang R, Gu J, Chen J, Ni J, Hung J, Wang
Z, Zhang X, Feng J and Ji L: High expression of PINK1 promotes
proliferation and chemoresistance of NSCLC. Oncol Rep.
37:2137–2146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB,
Gao SG and Chen XB: Roles and inhibitors of FAK in cancer: Current
advances and future directions. Front Pharmacol. 15:12742092024.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chuang HH, Zhen YY, Tsai YC, Chuang CH,
Hsiao M, Huang MS and Yang CJ: FAK in cancer: From mechanisms to
therapeutic strategies. Int J Mol Sci. 23:17262022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dawson JC, Serrels A, Stupack DG,
Schlaepfer DD and Frame MC: Targeting FAK in anticancer combination
therapies. Nat Rev Cancer. 21:313–324. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Canel M, Sławińska AD, Lonergan DW, Kallor
AA, Upstill-Goddard R, Davidson C, von Kriegsheim A, Biankin AV,
Byron A, Alfaro J and Serrels A: FAK suppresses antigen processing
and presentation to promote immune evasion in pancreatic cancer.
Gut. 73:131–155. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang P, Cao X, Guan M, Li D, Xiang H,
Peng Q, Zhou Y, Weng C, Fang X, Liu X, et al: CPNE8 promotes
gastric cancer metastasis by modulating focal adhesion pathway and
tumor microenvironment. Int J Biol Sci. 18:4932–4949. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang C, Yu Z, Yang S, Liu Y, Song J, Mao
J, Li M and Zhao Y: ZNF460-mediated circRPPH1 promotes TNBC
progression through ITGA5-induced FAK/PI3K/AKT activation in a
ceRNA manner. Mol Cancer. 23:332024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Paul R, Luo M, Mo X, Lu J, Yeo SK and Guan
JL: FAK activates AKT-mTOR signaling to promote the growth and
progression of MMTV-Wnt1-driven basal-like mammary tumors. Breast
Cancer Res. 22:592020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Roudsari NM, Lashgari NA, Momtaz S, Abaft
S, Jamali F, Safaiepour P, Narimisa K, Jackson G, Bishayee A,
Rezaei N, et al: Inhibitors of the PI3K/Akt/mTOR pathway in
prostate cancer chemoprevention and intervention. Pharmaceutics.
13:11952021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dong C, Wu J, Chen Y, Nie J and Chen C:
Activation of PI3K/AKT/mTOR pathway causes drug resistance in
breast cancer. Front Pharmacol. 12:6286902021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhang B, Li S, Ding J, Guo J, Ma Z and
Duan H: Rho-GTPases subfamily: Cellular defectors orchestrating
viral infection. Cell Mol Biol Lett. 30:552025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tseliou M, Al-Qahtani A, Alarifi S,
Alkahtani SH, Stournaras C and Sourvinos G: The role of RhoA, RhoB
and RhoC GTPases in Cell morphology, proliferation and migration in
human cytomegalovirus (HCMV) infected glioblastoma cells. Cell
Physiol Biochem. 38:94–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Merkel CD, Li Y, Raza Q, Stolz DB and
Kwiatkowski AV: Vinculin anchors contractile actin to the
cardiomyocyte adherens junction. Mol Biol Cell. 30:2639–2650. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lim J, Kang M, Ahn YH, Cho MS, Lee JH,
Kang JL and Choi YH: Comprehensive profiling of serum exosomes by a
multi-omics approach reveals potential diagnostic markers for brain
metastasis in lung cancer. Cancers (Basel). 17:19292025. View Article : Google Scholar : PubMed/NCBI
|
